MTCYBP34

Across TCGA pan-cancer cohorts, MTCYBP34 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated MTCYBP34 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTCYBP34 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCYBP34 expression acts as an unfavorable survival marker, although some lineages such as ESCA and LIHC show a favorable association.

MESO, STAD, and HNSC are the cancer types where MTCYBP34 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.317	0.584	.016	81	view →
STAD	DFS	Tertile	All	0.509	0.745	.009	63	view →
HNSC	OS	Tertile	All	0.259	0.609	.017	36	view →
LUAD	DFS	Tertile	IV	0.335	0.762	<.001	36	view →
THCA	OS	Tertile	III,IV	0.564	0.964	<.001	30	view →
SKCM	OS	Tertile	III,IV	0.241	0.701	.005	18	view →
ESCA	DFS	Tertile	III,IV	0.607	0.261	.008	18	view →
UCEC	OS	Tertile	IV	0.277	0.604	.019	18	view →
GBM	OS	Tertile	All	0.262	0.467	.014	15	view →
PCPG	OS	Tertile	All	0.670	0.945	.015	15	view →
KIRC	DFS	Tertile	IV	0.164	0.357	.030	12	view →
LIHC	DFS	Tertile	III,IV	1.000	0.130	.024	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

MTCYBP34–MESO (OS)

Open the MESO breakdown →